ArticleBMC psychiatry2025
Association between Purpureocillium, amino acid metabolism and cognitive function in drug-naïve, first-episode schizophrenia.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adjunctive transcranial direct current stimulation for cognitive improvement in schizophrenia: insights from a systematic review and exploratory meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Schizophrenia-associated alterations in fecal mycobiota and systemic immune dysfunction: a cohort study of elderly Chinese patients.Frontiers in immunology · 2025Article
- Dual-pathway protection: physical activity buffers the relationship between perceived stress and problematic smartphone use via social anxiety by a moderated mediation model in Chinese college students.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCognitive impairments in patients with schizophrenia (SCZ) is associated with poor social functioning and long-term prognosis. Our previous work suggests that some key fungal markers including Purpureocillium, are linked to SCZ.
methodsWe present a case-control study that includes 136 first-episode, drug-naïve patients with SCZ and 92 healthy controls (HCs). Untargeted liquid chromatography/mass spectrometry (LC/MS) was utilized to measure serum metabolite levels. The abundance of Purpureocillium was assessed using the internal transcribed spacer (ITS) analysis. Cognitive function was measured using the MATRICS Consensus Cognitive Battery.
resultsThe present study demonstrated significant declines in attention and alertness (AV), speed of processing (SOP) in individuals with SCZ. The abundance of Purpureocillium was found to have a negative correlation with multiple domains of cognitive function. Additionally, SCZ-related metabolic markers 2-Oxoarginine, N-Acetyl-serotonin, Ergothioneine, Isobutyric acid and Biotin were significantly associated with both the abundance of Purpureocillium and cognitive scores (SOP and AV). Mediation analyses revealed that the abundance of Purpureocillium in patients with SCZ had significant direct and indirect effects on SOP and AV) through metabolic markers (2-Oxoarginine, N-Acetyl-serotonin, Ergothioneine). Further, Purpureocillium and the metabolic markers were found to be correlated with inflammation and oxidative stress, both of which have been associated with pathogenesis of SCZ.
conclusionsOur findings suggest that Purpureocillium might be associated with cognitive impairments through its regulation on the metabolism of specific amino acids involved in inflammation and oxidative stress. A better understanding about the fungal-immune-metabolites association may lead to novel treatment approaches to improve cognitive function in patients with SCZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.